Russell J. Howard to Join Prima BioMed's Board of Directors

Russell J. Howard to Join Prima BioMed's Board of Directors 
SYDNEY, AUSTRALIA -- (Marketwired) -- 05/07/13 --  Prima BioMed Ltd
(ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the
"Company") is pleased to announce that Russell J. Howard, PhD, will
join Prima's Board as a Non-Executive Director with immediate effect. 
Dr. Howard brings a strong scientific background and significant
executive-level industry experience to Prima's Board. 
Dr. Howard, on his appointment: "I am very excited to join the Board
of Prima. I was drawn to the combination of CVac(TM) as a strong lead
product candidate in clinical development and a robust technology and
manufacturing platform that can drive Company value into the future.
I look forward to working with the Board, the management team, and
our scientific advisors as we advance Prima's leadership in the field
of personalized immunocellular therapeutics." 
Lucy Turnbull, AO, Prima's Chairman: "It is an honor and a pleasure
to welcome Dr. Howard as a Director. I believe his scientific and
business experience -- and his highly regarded international profile
-- will serve Prima well." 
Matthew Lehman, Prima's CEO: "I look forward to working with Dr.
Howard. His experience in developing technology platforms and
successfully monetizing technology applications and clinical products
are welcome skill sets to our Board of Directors." 
Dr. Russell Howard is an Australian scientist, CEO, and entrepreneur;
he was recently the overall winner of the 2013 Advance Global
Australian Award for his global impact on the biotechnology field and
green chemistry. He was a pioneer in the field of molecular
parasitology and in leading the commercialization of one of the most
important methods used widely today in molecular biology called "DNA
Shuffling" or "Molecular Breeding." He is an inventor on five patents
and has over 140 scientific publications.  
After earning his PhD in biochemistry from the University of
Melbourne, Dr. Howard has held positions at a number of leading
research laboratories around the world, including the
Immunoparasitology Laboratory at the Walter & Eliza Hall Institute in
Melbourne and the National Institutes of Health in Bethesda, Maryland
where he became a tenured investigator. In industry, Dr. Howard
worked at Schering-Plough's DNAX Research Institute of Molecular and
Cellular Biology in Palo Alto, California; was the President and
Scientific Director of Affymax, Inc.; and was the co-founder and CEO
of Maxygen, Inc. after its spin-out of Affymax-GlaxoWellcome. 
As Maxygen's CEO, Dr. Howard led its IPO and a secondary offering
raising a total of US$ 260 million in capital. Under Dr. Howard,
Maxygen successfully developed and partnered dozens of technology
applications and products. After leaving Maxygen in 2008, Dr. Howard
started the CleanTech company Oakbio, Inc. and remains involved in a
number of other innovative biotechnology companies. 
About Prima BioMed 
Prima BioMed is a globally active leader in the development of
personalized bio-therapeutic products for cancer. Prima is dedicated
to leveraging its technology and expertise to bring innovative
treatment options to market for patients and to maximize value to
shareholders. Prima's lead product is CVac(TM), an autologous
dendritic cell-based product currently in clinical trials for ovarian
cancer patients in remission and soon to be in trials for additional
cancer types. 
For further information please contact: 
USA Investor/Media:
Ms. Jessica Brown
Prima BioMed Ltd. 
+1 (919) 710-9061
jessica.brown@primabiomed.com.au  
Australia Investor/Media:
Mr. James Moses
Mandate Corporate
+61 (0) 420 991 574
james@mandatecorporate.com.au  
Europe Investor/Media:
Mr. Axel Muhlhaus
edicto GmbH
+49 (0) 69 905505-52
amuehlhaus@edicto.de 
 
 
Press spacebar to pause and continue. Press esc to stop.